Evonik and Halchemix Canada are pleased to announce the launch of a strategic partnership for the promotion of Evonik’s rumen-protected methionine product Mepron® in the Canadian market.
The agreement will see Halchemix become the exclusive distributor of Mepron® in Canada. The product is a superior methionine source that helps to boost milk production and reduce feed costs for the dairy industry.
Ken O’Halloran, Evonik’s Regional Vice President, North America, said: “Halchemix is well established in the Canadian market as a provider of well-researched feed additives, making them an ideal partner. Their products include amino acids, phytase, enzymes, and a dairy product line that includes rumen protected lysine and DCAD products.”
The use of Mepron® makes it easy to balance the ration for amino acids. This results in better herd health thanks to improved liver function, lower inflammation and less oxidative stress; higher dry matter intake followed by higher energy-corrected milk (ECM) yield; higher profitability (Income Over Feed Costs); lower nitrogen emissions and higher weaning weights of calves.
For more information on Mepron visit www.mepron.com
For additional information about Evonik in North America, please visit our website: http://corporate.evonik.us/region/north_america.
Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, customer-oriented innovative prowess and a trustful and performance-oriented corporate culture form the heart of Evonik’s corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world with more than 36,000 employees. In fiscal 2018, the enterprise generated sales of €15 billion and an operating profit (adjusted EBITDA) of €2.6 billion.
About Nutrition & Care
The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 8,200 employees, and generated sales of around
€4.6 billion in 2018.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.